Nanoparticle Delivery of Cancer Drugs

Annual Review of Medicine - Tập 63 Số 1 - Trang 185-198 - 2012
Andrew Z. Wang1,2, Róbert Langer3,4, Omid C. Farokhzad5
1Carolina Center for Nanotechnology Excellence, Chapel Hill, North Carolina, 27599;
2Carolina Center for Nanotechnology Excellence, Chapel Hill, North Carolina, 27599;; Lineberger Comprehensive Cancer Center, University of North Carolina School of Medicine, Chapel Hill, North Carolina 27599;
3Departments of Chemistry, Chemical Engineering, and Mechanical Engineering, and Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139;
4Massachusetts Institute of Technology–Harvard Center for Cancer Nanotechnology Excellence, Cambridge, Massachusetts 02139
5Laboratory of Nanomedicine and Biomaterials, Department of Anesthesiology, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts 02115;

Tóm tắt

Nanomedicine, the application of nanotechnology to medicine, enabled the development of nanoparticle therapeutic carriers. These drug carriers are passively targeted to tumors through the enhanced permeability and retention effect, so they are ideally suited for the delivery of chemotherapeutics in cancer treatment. Indeed, advances in nanomedicine have rapidly translated into clinical practice. To date, there are five clinically approved nanoparticle chemotherapeutics for cancer and many more under clinical investigation. In this review, we discuss the various nanoparticle drug delivery platforms and the important concepts involved in nanoparticle drug delivery. We also review the clinical data on the approved nanoparticle therapeutics as well as the nanotherapeutics under clinical investigation.

Từ khóa


Tài liệu tham khảo

Matsumura Y, 1986, Cancer Res., 46, 6387

10.1200/JCO.2005.04.937

10.1016/0009-3084(93)90071-A

10.1038/nrd1632

5. Deleted in proof

10.1097/01.cad.0000167902.53039.5a

10.1016/j.addr.2007.08.044

10.1158/1078-0432.CCR-05-1634

10.1021/la0502084

10.1038/sj.clpt.6100400

10.1158/0008-5472.CAN-04-2550

10.1073/pnas.0711714105

10.1021/ja051977c

14. Baker JR Jr. 2009. Dendrimer-based nanoparticles for cancer therapy. Hematol. Educ. Program Am. Soc. Hematol. Am. Soc. Hematol. pp. 708–19

10.1002/smll.201000523

10.1056/NEJMoa052122

10.1056/NEJMoa021491

10.1200/JCO.2005.10.017

10.1056/NEJMoa011795

10.1056/NEJM200104053441401

10.1517/14712598.8.8.1063

10.1126/science.330.6002.314

Jain RK, 2010, Nat. Rev., 7, 653

10.1073/pnas.95.8.4607

10.1023/A:1025785505977

10.1016/S0168-3659(99)00248-5

10.1016/j.coi.2005.11.008

10.1023/A:1011973625803

10.1073/pnas.0801763105

10.1007/s11095-008-9562-y

10.1016/j.phrs.2010.03.005

10.1021/nl900031y

10.1016/S0168-3659(00)00358-8

10.1042/BJ20031253

10.1073/pnas.0801763105

10.1056/NEJM198107163050305

10.1007/978-1-60761-609-2_26

10.1056/NEJM199809243391307

10.1200/JCO.2004.08.157

10.1093/annonc/mdh097

10.1200/JCO.2001.19.14.3312

10.1053/j.seminoncol.2004.08.003

10.1002/cncr.10201

10.1200/JCO.2001.19.5.1444

10.1200/JCO.1996.14.8.2353

Rowinsky EK, 1993, Semin. Oncol., 20, 1

10.1002/cncr.2820710442

10.1504/IJNM.2009.028116

10.1158/1078-0432.CCR-04-2291

10.1158/1078-0432.CCR-03-0655

10.1093/annonc/mdm374

10.1007/s10549-007-9591-y

10.1179/joc.2009.21.1.86

10.1016/j.lungcan.2009.06.017

10.1016/j.ejca.2010.07.015

10.1038/bjc.2011.6

10.1073/pnas.1011379108

10.1517/14656566.9.2.301

10.1016/j.jconrel.2011.03.007

10.1158/1078-0432.CCR-08-0515

10.1158/1078-0432.CCR-10-0387

10.1111/j.1349-7006.2009.01103.x

10.2174/156720108783331005

10.1038/sj.bjc.6602204

10.1007/s10637-010-9399-1

10.1111/j.1365-2796.2009.02191.x

10.1038/nature08956

10.1200/JCO.2010.30.5961

Thông tin
Thông tin xuất bản

Annual Review of Medicine

Tập 63 Số 1

185-198

Thông tin tác giả